Hormonal
Overexpression of SIRT1 in skeletal muscle inhibits muscle atrophy during fasting and denervation by deacetylating and blocking the activity of transcription factors FoxO1 and FoxO3, thereby suppressing the expression of atrogenes (atrogin1, MuRF1) and autophagy genes.
This research identifies SIRT1 as a key protector against muscle loss during starvation or nerve damage. While this paper uses genetic overexpression in mice, it suggests that boosting SIRT1 activity (potentially through lifestyle or future drugs) could prevent muscle wasting. For now, maintaining healthy SIRT1 levels through exercise and metabolic health may support muscle preservation.
SIRT1 overexpression blocks muscle atrophy induced by fasting and denervation and in fed mice promotes hypertrophy. SIRT1 overexpression reduces muscle wasting by blocking the activation of FoxO1 and 3. It thus prevents the induction of key atrogenes, including the muscle-specific ubiquitin ligases, atrogin1 and MuRF1, and multiple autophagy (Atg) genes and the increase in overall proteolysis.
Why this rating
High-quality in vivo animal studies (mice) with clear mechanistic pathways (deacetylation, gene expression, proteolysis rates), though not human clinical trials.
Source
SIRT1 Protein, by Blocking the Activities of Transcription Factors FoxO1 and FoxO3, Inhibits Muscle Atrophy and Promotes Muscle Growth
Dong Hoon Lee et al. · Journal of Biological Chemistry · 2013
DOI 10.1074/jbc.m113.489716
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →